Log In
Print this Print this

Contrave, Mysimba, naltrexone SR/bupropion SR (NB32)

  Manage Alerts
Collapse Summary General Information
Company Orexigen Therapeutics Inc.
DescriptionFixed-dose combination of naltrexone sustained release (SR) and bupropion SR
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationObesity
Indication DetailsTreat obesity
Regulatory Designation

U.S. - Special Protocol Assessment (Treat obesity);
U.S. - Undisclosed Review (Treat obesity);
EU - Standard Review (Treat obesity)


Takeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today